# Kubota Vision Inc. clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Kubota Vision Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kubota Vision Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/kubota-vision-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 7, 2026 | NCT07686289 | A Controlled Evaluation of Optical Defocus Parameters on Transient Changes in Axial Length Using Kubota Glass | Kubota Vision Inc. | Not applicable | Not yet recruiting | Myopia | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686289) |
| October 17, 2023 | NCT06085430 | Kubota Glass Parameter Refinement Study | Kubota Vision Inc. | Not applicable | Completed | Myopia, Myopia, Progressive, Vision Disorders | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06085430) |
| September 13, 2023 | NCT06034379 | Electronic Spectacles Versus Low Dose Atropine in Young Myopes | Kubota Vision Inc. | Not applicable | Recruiting | Myopia | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06034379) |
| June 21, 2022 | NCT05425108 | Binocular Peripheral Myopic Defocus Using a Clinical Prototype Device | Kubota Vision Inc. | Not applicable | Unknown | Myopia | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05425108) |
| August 5, 2020 | NCT04499703 | Evaluation of the Retinal Health Monitoring System Thickness Module | Kubota Vision Inc. | Observational | Completed | Macular Edema, Macular Degeneration | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04499703) |
| June 11, 2020 | NCT04428242 | Study Evaluating Retinal Health Monitoring System Thickness Module | Kubota Vision Inc. | Observational | Withdrawn | Macular Edema, Macular Degeneration | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04428242) |
| June 4, 2020 | NCT04415684 | Projected Peripheral Defocus Using a Wearable Device | Kubota Vision Inc. | Not applicable | Completed | Myopia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04415684) |
| May 14, 2020 | NCT04388020 | Effects of Projected Peripheral Defocus on Ocular Biometrics | Kubota Vision Inc. | Not applicable | Completed | Myopia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04388020) |
| November 20, 2019 | NCT04169802 | Study Evaluating Retinal Health Monitoring System Visual Acuity Module. | Kubota Vision Inc. | Observational | Completed | Age Related Macular Degeneration | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04169802) |
| December 11, 2018 | NCT03772665 | Safety and Efficacy of Emixustat in Stargardt Disease | Kubota Vision Inc. | Phase 3 | Completed | Stargardt Disease | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03772665) |
| January 26, 2017 | NCT03033108 | Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease | Kubota Vision Inc. | Phase 2 | Completed | Stargardt Disease, Macular Atrophy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03033108) |
| April 27, 2016 | NCT02753400 | Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy | Kubota Vision Inc. | Phase 2 | Completed | Proliferative Diabetic Retinopathy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02753400) |
| May 5, 2014 | NCT02130531 | Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular... | Kubota Vision Inc. | Phase 1 | Completed | Geographic Atrophy, Age-Related Macular Degeneration | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02130531) |
| March 4, 2013 | NCT01802866 | Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride | Kubota Vision Inc. | Phase 2/3 | Completed | Geographic Atrophy | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01802866) |
| July 2, 2012 | NCT01632137 | Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome | Kubota Vision Inc. | Phase 3 | Completed | Dry Eye Syndrome | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01632137) |
| August 5, 2011 | NCT01410188 | Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension | Kubota Vision Inc. | Phase 1/2 | Completed | Primary Open-angle Glaucoma, Ocular Hypertension | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01410188) |
| January 27, 2010 | NCT01057147 | Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea | Kubota Vision Inc. | Phase 2 | Completed | Keratoconjunctivitis Sicca, Dry Eye | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01057147) |
| December 7, 2009 | NCT01027013 | Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye | Kubota Vision Inc. | Phase 2 | Completed | Dry Eye Syndromes, Keratoconjunctivitis Sicca | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01027013) |
| October 28, 2009 | NCT01002950 | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy | Kubota Vision Inc. | Phase 2 | Completed | Dry Age-related Macular Degeneration, Geographic Atrophy | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01002950) |
| July 20, 2009 | NCT00942240 | Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects | Kubota Vision Inc. | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00942240) |
| June 23, 2008 | NCT00703183 | Safety and Tolerability of ACU-4429 | Kubota Vision Inc. | Phase 1 | Completed | Healthy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00703183) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Not applicable | 6 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Unknown | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myopia | 6 |
| Macular Degeneration | 4 |
| Dry Eye Syndromes | 3 |
| Geographic Atrophy | 3 |
| Stargardt Disease | 2 |
| Macular Edema | 2 |
| Retinal Vein Occlusion | 2 |
| Keratoconjunctivitis Sicca | 2 |
| Anetoderma | 1 |
| Myopia, Degenerative | 1 |
| Vision Disorders | 1 |
| Glaucoma, Open-Angle | 1 |
| Ocular Hypertension | 1 |
| Glaucoma | 1 |
| Diabetic Retinopathy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Surgery practices in the United States](https://specstream.ai/data/businesses/surgery-practices/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Natural gas utilities in the United States](https://specstream.ai/data/businesses/natural-gas-utilities/united-states)
- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
